Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S maintenance versus best available therapy in AML patients in complete remission after second-line salvage
2019-004134-42Phase 3Active
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of galinpepimut-s in acute myeloid leukemia (AML) (2 arms), sponsored by SELLAS Life Sciences Group, Inc. Primary endpoint: Median overall survival. Started Jul 2020; status: active.
02
Drugs
galinpepimut-s
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-004134-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004134-42.